Neurogenic licensed the schizophrenia immunoassay technology from the Weizmann Institute of Science, Rehovot, Israel. Through a former long-standing collaboration with the laboratory of Prof. Meir Shinitzky, a working prototype of the assay was developed and clinically tested on blood samples of pediatric, adolescent and adult schizophrenia patients in collaboration with researchers from the Department of Psychiatry, Faculty of Medicine, Tel Aviv University, Tel Aviv, the Beer Yaakov-Ness-Ziona Mental Health Center, Ness Ziona, the Geha Mental Health Center, Petach Tikva, and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel.

In March, 2017, Neurogenic moved into its new, state-of-the-art facility in the Weizmann Science Park, Ness Tziona, a short distance from the Weizmann Institute and the company's main clinical collaborator, the Beer Yaakov-Ness-Ziona Mental Health Center. A successful technology transfer process was completed by Weizmann and Neurogenic researchers in June, 2017 followed by miniaturization of the assay into a standard 96 well ELISA format. Currently, the research team is completing optimization of the assay procedures. An additional clinical trial is ongoing to validate the specificity and sensitivity of ELISA-based diagnostic-aid assay.